See more : Chen Lin Education Group Holdings Limited (1593.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Defence Therapeutics Inc. (DTCFF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Defence Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Manulife Financial Corp (MNQFF) Income Statement Analysis – Financial Results
- Findev Inc. (TNSGF) Income Statement Analysis – Financial Results
- Anemoi International Limited (AMOI.L) Income Statement Analysis – Financial Results
- Bangkok Land Public Company Limited (BLAND-R.BK) Income Statement Analysis – Financial Results
- eClerx Services Limited (ECLERX.BO) Income Statement Analysis – Financial Results
Defence Therapeutics Inc. (DTCFF)
About Defence Therapeutics Inc.
Defence Therapeutics Inc., a biotechnology company, engages in the research and development of biological/biosimilar therapeutic drugs for cancer and infectious diseases. Its proprietary platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. The company focuses on developing dendritic cell cancer vaccines; protein-based vaccine formulation against COVID and infectious diseases; and antibody drug conjugates (ADC) products targeting various cancers. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. Defence Therapeutics Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 13.82K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -13.82K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 3.86M | 3.58M | 3.76M | 1.16M | 433.45K | 0.00 |
| General & Administrative | 1.25M | 641.39K | 1.04M | 1.36M | 239.73K | 41.95K |
| Selling & Marketing | 1.71M | 1.96M | 2.52M | 341.10K | 0.00 | 41.90K |
| SG&A | 8.79M | 2.90M | 3.56M | 1.70M | 239.73K | 41.95K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 12.66M | 6.48M | 7.32M | 2.86M | 673.18K | 41.95K |
| Cost & Expenses | 12.66M | 6.48M | 7.32M | 2.86M | 673.18K | 41.95K |
| Interest Income | 0.00 | 6.81K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 262.93K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 70.94K | 13.82K | 7.27M | 2.83M | 673.18K | 41.95K |
| EBITDA | -12.68M | -6.48M | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -12.66M | -6.48M | -7.30M | -2.86M | -673.18K | -41.95K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -537.24K | -387.15K | -70.18K | 0.00 | 0.00 | 40.00K |
| Income Before Tax | -13.19M | -6.87M | -7.34M | -2.86M | -673.18K | -1.95K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 105.00K | 16.59K | -1.16M | -434.13K | -41.95 |
| Net Income | -13.19M | -6.76M | -7.34M | -2.86M | -673.18K | -1.95K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.30 | -0.17 | -0.20 | -0.11 | -0.02 | 0.00 |
| EPS Diluted | -0.30 | -0.17 | -0.20 | -0.11 | -0.02 | 0.00 |
| Weighted Avg Shares Out | 44.63M | 39.66M | 36.08M | 26.60M | 34.80M | 34.80M |
| Weighted Avg Shares Out (Dil) | 44.63M | 39.66M | 36.08M | 26.60M | 34.80M | 34.80M |
Defence's Accum(R)-mRNA Lipid Nanoparticles Elicit Antibody Response 2X Stronger than Standard mRNA Vaccines
Defence to Collaborate with Native Ads for Marketing Campaign
Defence's Broad and Versatile Accum(R) Technology Platform Focus on Cancer Therapeutics
Defence's Innovative Therapeutics Featured on Viewpoint with Dennis Quaid
Defence Successfully Completes the First Milestone of Its Collaboration Agreement with Orano
RETRANSMISSION: Defence to Present at the 9th Annual Immuno-Oncology 360º Summit in New-York February 7-10, 2023
Defence To Present at The 9th Annual Immuno-Oncology 360 Summit in New-York February 7-10, 2023
Source: https://incomestatements.info
Category: Stock Reports